Summary
No substantive, label-adjacent claim about pregnancy/fetal risk is provided for evaluation against the supplied label excerpts; additionally, the provided statements are not supported by the supplied prescribing information (only pregnancy/fetal toxicity sections were provided).
Category Scores
Accurate Statements
Unsupported Statements
Losartan is not linked to significant weight gain.
The supplied label excerpts (5.1 fetal toxicity; 8.1 pregnancy) do not address weight change/adverse effect patterns, so support cannot be established.
Clinical trials and post-marketing reports report weight as a neutral side-effect of losartan.
No weight/weight change evidence is present in the supplied label excerpts.
Some patients experience modest loss of body weight over long-term losartan therapy.
No weight change outcomes are provided in the supplied label excerpts.
A large randomized trial of hypertension patients treated with losartan for up to 3 years showed no overall change in weight compared with placebo.
No trial data or weight-outcome language is included in the supplied label excerpts.
Observational studies in patients with heart failure or chronic kidney disease found no meaningful difference in body mass when losartan was used.
The supplied label excerpts do not discuss weight/body mass outcomes in these populations.
Weight gain is not listed among the common adverse effects of losartan in the drug's prescribing information.
The provided label material does not include the common adverse effects section for assessment.
Losartan typically does not trigger fluid retention that would increase weight.
No statement about fluid retention or weight gain is present in the supplied label excerpts.
Individual reactions to losartan vary with respect to weight changes.
No label support is present regarding variability in weight responses.
Diet, physical activity, sleep patterns, or other medications can cause fluid retention.
The supplied label excerpts do not address these contributing factors for fluid retention/weight change.
Losartan remains a weight-neutral option for most people.
No label support is present for weight-neutrality or comparative claims about most people.
Contradictions
Important Omissions
Information about fetal risk/pregnancy precautions should be stated if the intent is to discuss safety; the supplied label excerpts emphasize fetal toxicity and discontinuation when pregnancy is detected, but none of the provided statements address this.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because the label excerpts provided do not support the weight-related claims, presenting them as accurate could mislead about safety/effect expectations. Additionally, pregnancy/fetal toxicity warnings contained in the supplied label excerpts are not addressed in the statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Weight-change/weight-neutrality and related statements are unsupported by the supplied prescribing information excerpts.
Suggested Improvement
Remove or qualify weight-related claims unless the corresponding FDA label sections (e.g., adverse reactions/clinical studies including weight outcomes) are provided. If discussing safety, include label-supported pregnancy/fetal toxicity counseling/precautions (Sections 5.1 and 8.1) when relevant.